Cambrex 3Q sales rose 2.3% to $57.8m. The company said the rise was primarily due to higher volumes of an API that utilises its polymeric drug delivery technology but was partially offset by lower sales of two APIs manufactured under long-term supply agreements.
Cambrex
Sunday, 8 November 2009
Cambrex sees 3Q sales rise
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment